Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
dermatitis/edema
L'enllaç es desa al porta-retalls
Pàgina 1 des de 26 resultats
Composition for preventing or treating atopic dermatitis comprising X-shape DNA structure as active ingredient
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
The present invention relates to a composition for preventing or treating atopic dermatitis, the composition including, as an active ingredient, X-shaped DNA formed by complementary binding of four oligonucleotides.
BACKGROUND ART
Atopy is a word of the Greek origin which means
Composition for preventing or treating atopic dermatitis including galenical extract or lactobacillus fermentation thereof
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This application is a National Stage Application under 35 U.S.C. .sctn.371 of PCT/KR2010/007523, filed 29 Oct. 2010, which claims the benefit of priority to Korean Patent Application No. 10-2010-0093901, filed 28 Sep. 2010, the disclosures of all of which are hereby incorporated by reference in
Indolylmaleimide derivatives
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
Indolylmaleimide derivatives
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein
R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl,
R.sub.b
Indolylmaleimide derivatives
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
Therapeutic treatment for skin disorders
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is broadly directed to a method of inhibiting or decreasing vascular permeability associated with dermal edema, e.g., induration, and especially the increased vascular permeability induced by vascular permeability factor
Triaza-cyclopenta[cd]indene derivatives
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This Application is a 371 of PCT/JP2005/000323, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is
Pyrrolopyrimidine and pyrrolotriazine derivatives
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This Application is a 371 of PCT/JP2005/000319, filed Jan. 6, 2005.
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety,
Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This Application is a 371 of PCT/JP2005/000318, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is
Pyrrolopyridine derivatives substituted with cyclic amino group
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating
Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating
Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The invention relates to the use of biologically active glutarimide derivatives or pharmaceutically acceptable salts thereof as agents for the treatment of eosinophilic diseases.
BACKGROUND
Eosinophils are cells of the innate immunity. They are produced in the bone marrow and
Hyaluronic acid-urea pharmaceutical compositions and uses
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the
Hyaluronic acid-urea pharmaceutical compositions and uses
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the
Hyaluronic acid-urea pharmaceutical compositions and uses
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
